Insights
More Articles
- EMA review for GSK, Vir's COVID-19 antibody launched
- Report: EU may not renew AstraZeneca, J&J vaccine deals
- Chinese may approve Pfizer/BioNTech vaccine this summer
- COVID-19 outbreak leads to shortage of vaccines in India
- New pregnancy prevention drug gains FDA nod
EMA review for GSK, Vir's COVID-19 antibody launched
A review has been initiated by the European Medicines Agency for VIR-7831, the investigational monoclonal antibody co-developed by GlaxoSmithKline and Vir Biotechnology as an early treatment for COVID-19. Included in the review will be an interim analysis of safety and efficacy data for 583 randomized patients, which showed the treatment reduced hospitalization or mortality by 85% in participants who received the monoclonal antibody in comparison to those given a placebo. PharmaTimes online (UK) (4/16)
Read full article now.
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!